Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKDB-308-2 is a probiotic-based live biotherapeutic product (LBP) currently under development by CKDBiO for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). As a microbial therapy, it is designed to modulate the gut microbiota and the gut-liver axis to address the underlying metabolic and inflammatory components of MASH, which was formerly known as non-alcoholic steatohepatitis (NASH). The drug candidate is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CKDB-308-2.